Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Recruiting 7Active not recruiting 4Not yet recruiting 2

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Genitourinary 7

Conditions

Breast Neoplasms 185Neoplasms 178Carcinoma, Non-Small-Cell Lung 162Prostatic Neoplasms 114Colorectal Neoplasms 111Lung Neoplasms 94Ovarian Neoplasms 85Neoplasm Metastasis 80Multiple Myeloma 75Pancreatic Neoplasms 73Leukemia, Myeloid, Acute 68Endometrial Neoplasms 53Stomach Neoplasms 49Squamous Cell Carcinoma of Head and Neck 48Melanoma 48Lymphoma 46Glioblastoma 45Recurrence 44Carcinoma, Renal Cell 44Urinary Bladder Neoplasms 42Carcinoma, Hepatocellular 41Brain Neoplasms 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Sarcoma 38Lymphoma, Non-Hodgkin 36Leukemia, Lymphocytic, Chronic, B-Cell 36Glioma 36Hematologic Neoplasms 35Small Cell Lung Carcinoma 34Esophageal Neoplasms 33

Interventions

testosterone 17 beta-cypionate 1enzalutamide 1darolutamide 1Pluvicto 1PSMA-617 1Gonadotropin-Releasing Hormone 1Blood Specimen Collection 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × Metastatic Castration-resistant Prostate Cancer × 30 days × Clear all
NCT06031805 2026-06-02

PROWESs

AstraZeneca

Recruiting
300 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06228053 2026-06-02

SYNERGY-201

Syntrix Biosystems, Inc.

Phase 2 Recruiting
53 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06514521 2026-06-01

Post Marketing Study on Pluvicto in Korea

Novartis

Recruiting
278 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06492122 2026-05-26

ProTACT

Full-Life Technologies GmbH

Phase 1 Recruiting
50 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06533644 2026-05-18

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

Syncromune, Inc.

Phase 2 Recruiting
91 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07244341 2026-05-15

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Daiichi Sankyo

Phase 1 Recruiting
60 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07476001 2026-05-15

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
12 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡